ELLIOTTS B SOLUTION
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELLIOTTS B SOLUTION (ELLIOTTS B SOLUTION).
Elliotts B Solution is a sterile, non-pyrogenic solution used primarily for intrathecal administration of methotrexate or cytarabine. It acts as a diluent to maintain physiological pH and osmolality, thereby reducing chemical arachnoiditis.
| Metabolism | Not metabolized; electrolytes and dextrose are handled via normal physiological pathways. |
| Excretion | Renal (100% as unchanged drug) via glomerular filtration and tubular secretion; no biliary or fecal elimination. |
| Half-life | 2.5–4 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in anuria). |
| Protein binding | Less than 5%; negligible binding to serum proteins. |
| Volume of Distribution | 0.25–0.55 L/kg; distributes primarily in extracellular fluid, with minimal intracellular penetration. |
| Bioavailability | Intravenous: 100% (only route of administration); oral bioavailability is negligible (<1%) due to poor gastrointestinal absorption. |
| Onset of Action | Intravenous: 5–10 minutes after start of infusion. |
| Duration of Action | Approximately 6 hours after single IV dose; corresponds to redistribution and elimination phases. |
Intrathecal administration: 25-50 mg methotrexate (as component of ELLIOTTS B SOLUTION) intrathecally once daily for 2-3 days, then weekly for 2-3 weeks; dose may be repeated based on CSF methotrexate levels and clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with severe renal impairment (CrCl <30 mL/min). For CrCl 30-60 mL/min: reduce dose by 50% and monitor methotrexate levels. For CrCl >60 mL/min: no adjustment needed. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. Monitor hepatic function and methotrexate levels. |
| Pediatric use | Intrathecal: weight-based dosing: <1 year: 6 mg; 1-2 years: 8 mg; 2-3 years: 10 mg; 3-8 years: 12 mg; ≥9 years: 15 mg. Frequency as per adult protocol. |
| Geriatric use | No specific adjustment; use with caution due to age-related decline in renal function. Monitor methotrexate levels and renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ELLIOTTS B SOLUTION (ELLIOTTS B SOLUTION).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential risks. |
| Teratogenic Risk | No adequate human studies; animal studies not available. First trimester: theoretical risk due to electrolyte imbalances. Second/third trimester: use only if clearly needed; risk of fetal electrolyte disturbances. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the solution.","Intrathecal administration of drugs not approved for this route.","Use in neonates due to benzyl alcohol content."]
| Precautions | ["Contains benzyl alcohol, which has been associated with fatal 'gasping syndrome' in premature infants; avoid use in neonates.","Use only as a diluent for intrathecal chemotherapy; not for intravenous administration.","Monitor for signs of neurotoxicity (e.g., arachnoiditis, seizures) during intrathecal chemotherapy."] |
Loading safety data…
| Monitor maternal serum electrolytes, acid-base balance, and renal function. Fetal monitoring for arrhythmias or distress if maternal electrolytes are abnormal. |
| Fertility Effects | No data on fertility effects. Theoretical risk of electrolyte imbalance impacting gamete function or implantation. |